New York-based UltraLinq has paid an undisclosed amount for Ulster University spinout Intelesens, an Irish medtech company that makes wearable, non-invasive, wireless devices for vital signs monitoring. The addition of Intelesens' algorithms for wireless detection of cardiac arrhythmias will enable UltraLinq "to make huge strides toward our end goal of providing cost-effective tools to improve the delivery of cardiovascular care globally," said UltraLinq CEO Stephen Farber.
UltraLinq buys Irish developer of vital signs monitoring devices
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.